aTyr Pharma, Inc. is a biotechnology company focused on developing innovative therapies to address rare diseases by leveraging its proprietary expertise in the biology of tRNA synthetases. The company specializes in advancing treatments that modulate the immune system, with a keen interest in conditions such as neurodegenerative diseases and muscle wasting disorders. aTyr employs a unique platform that seeks to harness the natural functions of these proteins, aiming to deliver potential solutions that improve patients' quality of life and address unmet medical needs. Through rigorous research and clinical development processes, aTyr Pharma strives to bring transformative therapies to market. Read More
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of the securities laws.
ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications.
